<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="734">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343092</url>
  </required_header>
  <id_info>
    <org_study_id>PRO20040001</org_study_id>
    <nct_id>NCT04343092</nct_id>
  </id_info>
  <brief_title>Efficacy of Ivermectin as Add on Therapy in COVID19 Patients</brief_title>
  <official_title>Efficacy of Ivermectin as Add on Therapy in COVID19 Patients: A Pilot Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Baghdad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Baghdad</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing the efficacy of add on therapy of Ivermectin in covid19 patients to non
      ivermermectin group
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparing the efficacy of add on therapy of single dose 12mg Ivermectin to hydroxychloroquine
      (HCQ) and azithromycin (AZT) in covid19 patients to non ivermermectin group ( HCQ+AZT)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2020</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cured patients</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of patients cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for covid19 (PCR) in addtion to Chest xary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean time to cure of the covid 19 patients</measure>
    <time_frame>4 week</time_frame>
    <description>comparing mean time of cure of patients in IVM group with the the non IVM group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>COVID 19</condition>
  <arm_group>
    <arm_group_label>Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin 12 mg /weekly )+ Hydroxychloroquine 400mg/daily + azithromycin 500mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquin+ azithromycin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Hydroxychloroquine 400mg/daily+ azithromycin 500mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin (IVM)</intervention_name>
    <description>Ivermectin 0.2 mg /kg (single dose at once =2 tablets of 6mg/weekly</description>
    <arm_group_label>Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT)</arm_group_label>
    <other_name>Ivermectin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -1. Patients with age above 18 years and any gender with definite Dx of covid19 and
        pneumonia in the ward according to the clinical, laboratory, and imaging criteria.

        2. Understands and agrees to comply with planned study procedures.

        Exclusion Criteria:

          1. Patients with hypersensitivity or severe adverse effects to Ivermectin

          2. Renal impairment

          3. Hepatic impairment.

          4. Pregnancy or a desire to become pregnant (drug considered pregnancy category c)

          5. Breast feeding.

          6. Patient with covid 19 positive and mild no pneumonia

          7. Children under the age of five or those who weigh less than 15 kilograms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faiq I Gorial, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Baghdad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jawad I. Rasheed</last_name>
    <role>Study Chair</role>
    <affiliation>Arab Board for Health Specialiazation in Iraq</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Directorate of Medical City</name>
      <address>
        <city>Bagdad</city>
        <state>Baghdad</state>
        <zip>964</zip>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 5, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Baghdad</investigator_affiliation>
    <investigator_full_name>Faiq Gorial</investigator_full_name>
    <investigator_title>Professor and consultant rheumatologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>June 11, 2020</submitted>
    <returned>June 16, 2020</returned>
    <submitted>July 1, 2020</submitted>
    <returned>July 6, 2020</returned>
    <submitted>July 12, 2020</submitted>
    <returned>July 14, 2020</returned>
    <submitted>July 15, 2020</submitted>
    <returned>July 17, 2020</returned>
    <submitted>July 17, 2020</submitted>
    <returned>July 20, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

